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The usefulness of scid mice bearing endogenous Pneumocystis carinii infection as a
model for experimental chemotherapy was examined using standard compounds
known to be effective against P. carinii. Trimethoprim/sulphamethoxazole was able to
reduce pulmonary P. carinii cysts in a dose-dependent manner within the dose range
studied (10/50 to 100/500 TMP/SMX mg/kg/d, bd, po, 5 days per week for 30
treatments). However, alterations in associated symptoms of infection (reduced body
weight, increased lung weight, increased blood leucocytes and erythrocytes), was
apparently not linearly dose-dependent. Blood and lung lavage fluid levels of
sulphamethoxazole one hour post administration of trimethoprim/sulphamethoxazole
was dose-dependent, but not linear with dose, and was apparently correlated to cyst
reduction; trimethoprim was below the limit of detection at this time. Treatment of
mice with 100/500 mg/kg/day trimethoprim/ sulphamethoxazole required 2 weeks (bd
for 10 days of treatment) before changes in indices of infection became significant.
Pentamidine (20 mg/kg, sc, three times per week for 3 weeks) was nearly as effective
as high-dose trimethoprim/ sulphamethoxazole in reducing cysts, whereas lower doses
were ineffective. Despite being unable to reduce pulmonary P. carinii infection, even
low doses of pentamidine (6 or 2 mg/kg, sc, three times per week for 3 weeks) were
able to reduce lung weights and blood leucocyte levels. This model of pulmonary P.
carinii infections is amenable to chemotherapeutic intervention in an apparently
dose-dependent fashion, and can be used to evaluate the capacity of compounds to
eradicate P. carinii and resolve signs of infection.
Introduction
Pneumocystis carinii is recognised as a pathogen of immunosuppressed patients and is
particularly common in patients suffering from AIDS. Although both experimental and
clinical research has demonstrated both trimethoprim/sulphamethoxazole and aerosol
pentamidine to be effective agents (Masur et al., 1989; Davey & Masur, 1990; Bartlett
& Smith, 1991; Sraulian & Walzer, 1992), particularly in primary or secondary
prophylaxis, the incidence of failures, development of infections refractory to treatment
(especially after inadequate secondary phophylaxis), and severe side-effects, clearly
indicate the need for novel therapeutic approaches. Furthermore, recent clinical
experience has demonstrated P. carinii to be present in extra-pulmonary sites, including
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patients that had received aerosol pentamidine prophylaxis (Dembinski et al., 1990; Telak
et al., 1990), and suggests the possibility that this route of pentamidine administration
is incapable of suppressing the growth of this organism at distal sites, thus rendering this
form of prophylaxis potentially ineffectual in the long term.
The usual in-vivo model for experimental P. carinii research is the dexamethasone
immunosuppressed rat, which relies on chemical immunosuppression to allow either the
growth of endogenous P. carinii (Hughes et al., 1974; Kovacs et al., 1988; Masur et al.,
1989; Davey & Masur, 1990), or exogenous P. carinii following intratracheal infection
(Bartlett et al., 1990; Boylan & Current, 1992). Cortisone-immunosuppressed mice have
also been used (Walzer, Powell & Yoneda, 1979a; Powles et al., 1992). Although long
recognised as an endogenous, lethal infection of genetically immunocompromised mice
(Ueda et al., 1977; Walzer et al., 1977; Sundberg et al., 1989), including the severe
combined immunodeficient (scid) mouse strain (Walzer et al., 1979a; Shultz et al., 1989),
only recently have communications thoroughly describing the pathology of pulmonary
P. carinii infection in scid mice appeared (Roths et al., 1990; Chen, Mills & Harmsen,
1992). Recent research has exploited the scid mouse to demonstrate the essential role of
CD4+ (Harmsen & Stankiewicz, 1990; Roths & Sidman, 1992), but not CD8+ (Roths &
Sidman, 1992) T-cells in resistance to the disease. Furthermore, scid mice have been used
to demonstrate the importance of interleukin-1 (Chen et al., 1992) and endogenous
tumour necrosis factor, but not interferon y (Chen, Havell & Harmsen, 1992a) or IL-6
(Chen et al., 19936), in the resistance to infection. P. carinii-inkcted scid mice have also
been used to demonstrate the potential of passive immune therapy (Roths & Sidman,
1993) and to demonstrate that latent infections may not be the sole source of P. carinii
in immunocompromised patients (Chen, Gigliotti & Harmsen, 1993).
However, throughout these studies, little attention has been paid to the suitability of P.
carinii-'mfected scid mice for experimental chemotherapeutic intervention. As previous
communications indicated the efficacy of trimethoprim/sulphamethoxazole as anti-P.
carinii therapy in the promotion of survival of scid mice (Walzer et al., 1979a; Shultz et al.,
1989), the purpose of the present research was to appraise the P. carzmV-infected scid
mouse as a potential model for the evaluation of novel chemotherapeutic agents. As
trimethoprim/sulphamethoxazole and pentamidine are used clinically and as reference
agents in experimental studies (Hughes & Smith, 1984; Clarkson, Williams & Rosenberg,
1988; Kovacs et al., 1988; Hughes et al., 1990; Bartlett et al., 1991; Brun-Pascaud et al.,
1992; Walzer et al., 1992Z»), these compounds were used to demonstrate that pulmonary
P. carinii infection in scid mice is amenable to chemotherapeutic intervention.
Materials and methods
Scid mice
Scid mice, proven to be positive for pulmonary P. carinii infection by diagnostic
microscopy (Giemsa staining of lung histological sections), were housed at Ciba-Geigy.
Based upon previous studies (Roths et al., 1990), male or female mice over 90 days of
age were obtained for treatment studies. P. carinii free scid mice (from a different colony)
were also used. Animals were randomised to treatment groups, marked for later
identification and housed in a restricted-access room, in filter-topped cages containing
sterilised wood shaving bedding. Animals received autoclaved water and food
(double-vitamin) ad libitum. Personnel handling the animals wore "dedicated use"
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laboratory coats, masks and gloves, and cages were only opened under a vertical-flow
hood. In two separate experiments, sentinel (DBA) mice housed with the scid mice were
screened for the development of antibodies to a variety of viruses (including pneumonia
virus of mice; see Bray et al., 1993; Roths, Smith & Sidman, 1993) and mycoplasma and
found to be negative. Determination of possible contamination of the mice with bacteria
by culture of lung homogenate and of blood on Brain Heart Infusion agar (Difco) was
performed on each mouse. Significant numbers of bacteria were not recovered at any time
to suggest bacterial infection to compromise the experiments. The experimental protocols
involving animals were approved by the ethics committee of the Kantonales Veterinaramt
of Basel Stadt.
Determination of pulmonary P. carinii cysts
The methods to determine pulmonary P. carinii were based upon those described
for the collection of cysts from lung homogenates (Walzer et al., 1979c). After the animal
was killed (0-1 mL ip T61; Hoechst Veterinarimar), blood was collected from the inferior
vena cava into 1 mL syringes which had been rinsed with EDTA (10% w/v). Lungs were
removed intact, weighed, cut into small pieces and then transferred to a glass homogeniser
and homogenised in the presence of 150 /iL of Hanks' buffered salts solution containing
100 U/mL heparin (Roche). Five mL of Hanks' solution supplemented with 0-2% w/v
collagenase (Boehringer-Mannheim), 0-2% w/v hyaluronidase (Boehringer-Mannheim)
and 25 U/mL heparin was added, and the sample again homogenised. The entire contents
were then transferred to a 50 mL Erlenmeyer flask and incubated with shaking for one
hour at 37°C. The homogenate was then centrifuged (15 min at 2000 g, 20°C), and the
pellet (containing P. carinii cysts) was resuspended in 100 to 2000 /iL Hanks' solution
containing 100 U/mL heparin. A 50 /iL aliquot of this suspension was mixed with 10 /iL
methylene blue (Loffler's; E. Merck product number 1287); the remainder of this
suspension could be frozen (—20°C) without apparent loss of cysts. After 10 min at room
temperature, 2 /iL of the stained suspension was spread across a 7 mm2 square section
of clear glass present in a black coated microscope slide (Huber and Co. AG, Reinach,
Switzerland) and allowed to dry in air. Three edge to edge lines were evaluated for the
number of cysts (1000 x oil immersion) by at least three independent observers. Previous
determination of the number of lines present in the 7 mm2 area (under oil immersion)
combined with the known volume of suspension spread within the 7 mm2 area and the
original weight of the lung allowed the determination of the numbers of cysts per g (wet
weight) of lung homogenate. Depending upon the weight of lung, the limit of detectability
was approximately log 4 cysts/g lung. With this methylene blue staining procedure, cysts
were stained with a variable intensity of blue, but sufficient to distinguish them
from the background material. Some slides were also stained using Toluidine blue
or Diff-Quik; using this latter staining method cysts from scid mice demonstrate
characteristic morphology (non-staining cyst wall surrounding punctate intra-cyst forms;
see Bartlett & Smith, 1991).
Blood cell counting
Total erythrocyte and leucocyte cell counts were determined by a Sysmex model CC-170
or E-5000 blood cell analyser (TDA Corp., Kobe, Japan) following the directions of the
manufacturer.
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Antimicrobial agents
Trimethoprim/sulphamethoxazole (Bactrim; Roche) was obtained commercially
as sucrose-free syrup containing 16 mg/mL trimethoprim and 80 mg/mL sulpha-
methoxazole and, when necessary, diluted in pyrogen-free saline (0-9% w/v). Pentamidine
was obtained commercially as a dry powder (Pentacarinat 300; Rhone-Poulenc) and was
dissolved in pyrogen-free saline (0-9% w/v). Doses were adjusted weekly according to
changes in body weight. Unless otherwise indicated, mice were treated with
trimethoprim/sulphamethoxazole (po by gavage) twice per day (q 12 h), 5 days per week
for a total of 30 doses, or with pentamidine (sc) three times per week (Monday,
Wednesday, Friday) for a total of nine doses. Treatment groups consisted of five to ten
mice per group as indicated in the figure legends.
Assay of trimethoprim and sulphamethoxazole
Concentrations of trimethoprim, sulphamethoxazole and N-acetyl sulphamethoxazole
were determined by reversed phase HPLC (Blaser et al., 1993). Briefly, protein was
removed from serum samples by adding a five-fold volume of 0-33 M perchloric acid
and subsequent centrifugation. Lung lavage fluids were collected by lavaging the
lungs of killed mice three times with 1 mL of phosphate buffer containing 1 U/mL heparin
and measuring the volume obtained. Protein was not removed from lung
lavage fluids before HPLC analyses. Trimethoprim, sulphamethoxazole and JV-acetyl
sulphamethoxazole were separated using a Nova-Pak C|g column (Waters) eluted with
a mixture of 85% (v/v) phosphate buffer (0-01 M, pH 30) and 15% (v/v) acetonitrile at
a flow rate of 1-6 mL/min, detected by a photodiode array detector, and concentrations
corrected by external standardisation. The limits of detection of trimethoprim and
sulphamethoxazole or JV-acetyl sulphamethoxazole were 0-5 and 10mg/L for serum
specimens and 01 and 0-2 mg/L for lung lavage fluids, respectively. Coefficients of
variation for 8-12 repeated assays per analyte, specimen type and concentration ranged
from 1-3 to 5-2%.
Histological evaluations
After bleeding from the vena cava, lungs were excised and fixed by immersion in 4%
neutral phosphate-buffered formalin. Tissues were trimmed, embedded in Paraplast
(Zahner Electronic AG, Kalbrunn, Switzerland) and 4 pm longitudinal sections were
stained either with haematoxylin and eosin (for general pathology) or Periodic
Acid-SchifTs reagent (PAS; for P. carinii cyst walls and foamy material in alveoli) or
Grocott's Methenamine Silver stain (for P. carinii cyst walls) (Luna, 1992). Three sections
per lung were examined.
Statistical evaluations
Data presented are means ± S.E.M. Statistical evaluation of the data (ANOVA [Fisher's
PLSD], paired /-test, Spearman's Rank Correlation Coefficient (r.) used a commercial
program (Statview II, Abacus Concepts, Berkley, California). When cysts counts were
below the limit of detection, values for those samples were placed at the limit of detection
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(that is, one cyst/lung). However, this imposes possible underestimates of the levels of
statistical significance.
Results
Validation of cyst enumeration method
Initial studies of Diff-Quik-stained scid mouse lung homogenates revealed stained bodies
with morphologies and sizes comparable to previously published observations describing
P. carinii in rat and human samples (see Masur et al., 1989; Davey & Masur, 1990; Bartlett
& Smith, 1991; Smulian & Walzer, 1992). That the scid mice bred by us were indeed
positive for P. carinii was confirmed by the demonstration that bodies of the size and
morphology of P. carinii were present in Giemsa-stained histological lung sections (not
presented). Furthermore, as presented below, animals treated with trimethoprim/sul-
phamethoxazole, an agent known to be effective against P. carinii (see Masur et al., 1989;
Davey & Masur, 1990; Bartlett & Smith, 1991; Smulian & Walzer, 1992), did not contain
such bodies.
Although devoid of punctate intra-cyst forms, the methylene blue method stained
bodies of similar size and morphology to the Diff-Quik and Toluidine blue methods.
When individual lung samples were serially diluted, all staining methods yielded a linear
response of cyst count over a ten-fold range (data not presented). The cyst counts between
the different methods correlated strongly (methylene blue and Toluidine blue, r, = 0-952,
P = 001; methylene blue and Diff-Quik, r, = 0-976, P = 001). Furthermore,
determination of the cyst count in the lungs of 13 mice (range approximately log 4-5—6-8
cysts/g lung) demonstrated a good correlation between the methylene blue and Diff-Quik
(r, = 0-937, P = 00012) staining methods (data not presented). However, the methylene
blue staining consistently provided higher cyst counts than the Diff-Quik method. As the
methylene blue method appeared to stain remaining lung tissue less avidly, this
observation is likely due to the detection of cysts that would have been obscured by lung
tissue staining strongly by the Diff-Quik method. For the methylene blue method, the
range of cyst counts between individuals was on average 23% of the mean; the coefficient
of variation was 12%. The methylene blue stain was used for all of the experiments
reported below.
Progression of P. carinii infection in scid mice
Based upon previous information (Custer, Bosma & Bosma, 1985; Roths et al., 1990),
the body weights, lung weights, pulmonary P. carinii cyst counts and circulating
white blood cell (WBC) and red blood cell (RBC) levels were measured in scid mice of
different ages (Table I). As scid mice age, the levels of lung P. carinii cysts increase; that
the cysts/g lung apparently decrease after 91 days of age may reflect the extensive increase
in lung weight. This increase in P. carinii was correlated to increased lung weights,
increased circulating WBC levels and to the slight increase in RBC levels, and in mice
over 90 days of age, reduced body weights (for all rt, P < 0001). Based upon this
information, these indices, which are apparently associated with the progression of P.
carinii infection, were chosen as additional indices to monitor the efficacy of therapy when
administered to mice of approximately 90 days of age. Previous experiments established
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the uniformity of pulmonary cyst counts in 90 days old scid mice in that all mice were
infected with similar P. carinii cyst counts (not presented).
Effect of trimethoprim/sulphamethoxazole treatment on P. carinii infection in scid mice
Scid mice were administered trimethoprim/sulphamethoxazole in order to determine
if this agent, known to be efficacious in clinical and experimental studies, would
demonstrate any dose-dependent reduction in pulmonary P. carinii cysts or alleviation
of symptoms of infection. Scid mice (n = 10 per group) were treated with trimethoprim/
sulphamethoxazole administered twice daily, po for 30 applications over a 21 day
period (ten treatments per week) at doses of 100/500, 50/250, 25/125, 10/50
and 0/0 mg/kg/day trimethoprim/sulphamethoxazole. One day after the last treatment
the mice were killed and the body weights (Figure l(a)), pulmonary cyst counts
(Figure l(b)), lung weights (Figure l(c)) and blood WBC levels (Figure l(d)) were
determined.
At the end of treatment, all trimethoprim/sulphamethoxazole-treated mice had
significantly increased body weight compared with saline-treated mice (Figure l(a);
P < 001) whose body weight had remained unchanged during the course of treatment
(before treatment: 22-6 ± 0-9 g, after saline treatment: 221 ±0-5; P = 0-6, paired
/-test). However, there were no significant differences in the weight of mice treated
with different trimethoprim/sulphamethoxazole dosages (ANOVA, P > 0-05). A
dose-dependent reduction in pulmonary cysts was observed (Figure l(b)) and ANOVA
analysis demonstrated significant differences (P < 001) between the effectiveness of
various doses to reduce the lung cyst count, with 100/500 mg/kg/day being most effective
at reducing pulmonary cyst burden (log 4-3 ± 002 cysts/g lung vs log 6-9 ± 009 cysts/g
lung for saline treated, infected controls). Note that although 10/50 mg/kg/d
trimethoprim/sulphamethoxazole treatment reduced cyst levels compared with infected
controls, the difference did not quite reach statistical significance compared with
saline-treated infected controls (P = 006).
All doses of trimethoprim/sulphamethoxazole were effective in reducing lungs weights
below that of saline-treated, infected, control mice (0-48 + 002 g), without
demonstrating a linear dose-dependency (Figure l(c)). All trimethoprim/sulphamethox-
azole doses also reduced the circulating WBC levels (Figure l(d)) compared with the level
ofcontrol mice (WBC 11 02 ± 0-41 x 109 L blood), with the two lower doses (25/125 and
Table I. Progression of P. carinii infection in scid mice"
Days of
age
Body weight
(g)
P. carinii infected
35
63
91
125
Uninfected
92
21
24
23
20
26
t
t
±
1
1
1
2
2
Lung
0130
0153
0-36
0-47
0159
; weight
(g)
±0004
±0005
±003
±002
±0014
Log (cysts/g lung)
5-38 ±
6-6 ±
7-31 ±
6-9 ±
< 4
006
01
005
01
•5
WBC/L
2
5'
4
6
2
(x
060
790
530
033
100
: 11
-|-
-f-
±
t
±
blood
3')
0151
0-689
0-416
0-592
0-400
RBC/L
(x
0-82
0-9
102
110
0-93
1(
-j-
±
±
±
blood
0
0
0
0
)
04
02
•03
•04
004
•Male scid mice (n = 10/age) were killed at the indicated ages and their body and lung weights, lung P. carinii
cyst load, and circulating leucocytes (WBC) and erythrocytes (RBC) determined. Values are means ± S.E.M.
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Figure 1. Tnmethoprim/sulphamethoxazole (TMP/SMX) treatment of scid mice infected with P. carinii. scid
mice of 91 days of age (n = 10/group) were treated po, bd, 5 days per week, with various doses of
trimethoprim/sulphamethoxazole (0/0,10/50,25/125,50/250 or 100/500 mg/kg/day) fora total of 30 doses. One
day after treatment, mice were killed and body weights (a), lung cyst P. carinii burden (b), lung weights (c) and
circulating leucocytes (d) were determined. Symbols represent mean values ± S.E.M.
10/50 mg/kg/d doses) resulting in a similar decrease (P > 005; ANOVA) and the
two higher doses (100/500 and 50/250 mg/kg/day) being indistinguishable (P > 005:
ANOVA), but reducing the WBC levels further than the lower doses (ANOVA
P < 001 vs 10/50 or 25/125 mg/kg/day). Only the two highest doses of trimethoprim/
sulphamethoxazole significantly (P < 001 ANOVA) reduced blood RBC levels
compared with saline-treated infected controls (not shown): 100/500 mg/kg/d,
1-04 ± 002 x 1013 RBC/L; 50/250 mg/kg/day, 1-03 ± 0-03 x 1013 RBC/L; saline
treated, infected controls, 1-2 ± 003 x 10'3 RBC/L. However, when considering
calculated haematocrit values, there were no significant differences between groups
(not presented) These results indicate that although the reduction in numbers of
P. carinii in the lungs of scid mice is apparently linearly dependent upon the
dose of trimethoprim/ sulphamethoxazole, the other indicators of progress
(or resolution) of P. carinii infections may not always respond in a linear, dose-dependent
manner.
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Histological evaluation of the effect of trimethoprim/sulphamethoxazole treatment
Infected, untreated control mice showed a moderate to marked pneumonia caused
by P. carinii. The alveoli were filled with a foamy mass consisting of coalesced
macrophages and P. carinii organisms (positive staining with PAS). P. carinii cysts
could also be demonstrated with Grocott's methenamine silver stain (not shown).
Infiltration with polymorphonuclear neutrophil granulocytes, lymphocytes and
macrophages as well as hypertrophy of the alveolar epithelium were present. Although
all lung lobes were affected, the distribution throughout the individual lobes was
patchy, but there was little difference in the severity of pathology between the lobes.
Treatment with different doses of trimethoprim/sulphamethoxazole reduced the
severity of pneumonia in an apparently dose-dependent manner (Table II). The amount
of PAS-staining material (indicative of the presence of P. carinii; Luna, 1992) was
successively reduced at each trimethoprim/ sulphamethoxazole dose (Figure 2), which
is in congruence with the quantitative data of cyst counts (Figure l(b)). Furthermore,
trimethoprim/sulphamethoxazole treatment was also associated with a reduction of
inflammatory changes that was also apparently related to the dose used. At higher
Table II. Histological evaluation of the effect of trimethoprim/sulphamethoxazole. Treatment of
P. carinii infected scid mice"
TMP/SMX dose
(mg/kg/day, po)
100/500
50/250
25/125
10/50
0/0
Animal
number
1
2
3
1
2
3
4
1
2
3
4
1
2
3
4
1
2
3
4
Severity of
infection *
minimal
minimal-marked''
minimal-slight
slight-moderate
minimal-slight
slight-moderate
slight-moderate
slight-moderate
marked
moderate
slight-moderate
moderate
moderate
moderate
slight-moderate
moderate
moderate
moderate
marked
Distribution'
patchy
patchy-diffuse, severity differs between lobes
patchy
patchy, severity differs between lobes
patchy
patchy-diffuse, severity differs between lobes
patchy, severity differs between lobes
patchy, severity differs between lobes
diffuse
patchy
patchy, severity differs between lobes
patchy
patchy to diffuse
patchy
patchy, severity differs between lobes
patchy
patchy
patchy
diffuse
'scid mice, 90 days of age, were treated with trimethoprim/sulphamethoxazole (TMP/SMX), bd, po, 5 days
per week, for a total of 30 doses. One day after the end of treatment, the lungs were removed and processed
for histological examination as described in Materials and methods.
*Grading: minimal, <25% of the alveolar area affected (cysts, macrophages, inflammatory cells/fibrin);
slight, 25-50% of the alveolar affected; moderate, 50-75% of alveolar area affected; marked, > 75% of alveolar
area affected.
'Distribution: Patchy, irregular distribution of cysts, mainly concentrated adjacent to bronchi or in subpleural
regions; diffuse, regular distribution throughout lobe.
'Marked accumulation of alveolar macrophages and intact cysts not clearly distinguishable from
disintegrating cysts.
100/500
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Figure 2. Histological evaluation of the lungs of scid mice treated with various doses of
trimethoprim/sulphamethoxazole. P. carinii infected scid mice 90 days of age (n = 5/group) were treated po,
bd, 5 days per week, with various doses of trimethoprim/sulphamethoxazole (0/0, 10/50, 25/125, 50/250 or
100/500 mg/kg/day) for a total of 30 doses. One day following the end of treatment, mice were killed and the
lungs excised and immersed in 4% neutral phosphate buffered formalin, sectioned, and stained with PAS.
Samples with representative histological features are presented.
doses, lung architecture was almost completely restored (Figure 2). Similar histological
pictures of dose-dependent reduction in P. carinii numbers, and lung pathology, were
observed from lung sections stained by haematoxylin and eosin or Grocott's
methenamine silver stain (not shown).
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Correlation ofanti-P. carinii activity with trimethoprim/sulphamethoxazole levels in body
fluids
Measurement of the concentrations of trimethoprim, sulphamethoxazole and jV-acetyl
sulphamethoxazole within body fluids was performed by HPLC. After administering
9 treatments of trimethoprim/sulphamethoxazole (0/0, 10/50, 25/125, 50/250 and
100/500 mg/kg/d, bd; n = 8 per group) to scid mice, blood and lung lavage fluids were
obtained after killing the mice 1 h after the last treatment. As shown in Figure 3(a),
although the serum level of TV-acetyl sulphamethoxazole was apparently linear with
respect to trimethoprim/sulphamethoxazole dose, the concentration of sulphamethoxa-
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Figure 3. Effect of dose on the body fluid levels of trimethoprim, sulphamethoxazole and JV-acetyl
sulphamethoxazole in scid mice. P. carinii infected scid mice (n = 8/group) were administered 9 treatments of
trimethoprim/sulphamethoxazole (0/0, 10/50, 25/125, 50/250 or 100/500 mg/lcg/day), and serum and lung
lavage fluid were obtained one hour after the last treatment. The levels of trimethoprim, sulphamethoxazole
and W-acetyl sulphamethoxazole within serum (a) and lung lavage fluid (b) were determined by HPLC. Symbols
represent mean values ± S.E.M. and symbols within stippled areas represent samples below the limit of
detectability. Numbers indicate the daily dose of trimethoprim/sulphamethoxazole in mg/kg. All
photographs x 200. O, Sulphamethoxazole; • , JV-sulphamethoxazole; • , trimethoprim.
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Figure 4. Comparison of body fluid sulphamethoxazole levels and final lung cyst levels. The concentrations
of sulphamethoxazole were obtained from P. carinii infected scid mice (n •= 8/group) receiving 9
trimethoprim/sulphamethoxazole treatments as described in Figure 2, and the lung cyst counts were determined
from mice (n = 10/group) receiving 30 trimethoprim/sulphamethoxazole treatments as described in Figure 1.
Symbols represent mean values ± S.E.M. derived from experiments run in parallel. Panel A compares serum
sulphamethoxazole levels with final cyst counts and panel B compares cyst counts with lung lavage fluid
sulphamethoxazole concentration.
zole was not, although the sulphamethoxazole concentrations were all significantly
different from each other (ANOVA; P < 001). Surprisingly, at 1 h post administration,
trimethoprim was undetectable (<0-5 mg/L). A non-linear response of lung lavage fluid
sulphamethoxazole concentration to dose was also observed (Figure 3(b)); neither
trimethoprim (< 0-5 mg/L) nor JV-acetyl sulphamethoxazole (<0-2 mg/L) was detected.
Maximal sulphamethoxazole penetration into lung lavage fluid (1-3% of serum levels)
occurred with 50/250 mg/kg/day trimethoprim/sulphamethoxazole, with no greater
per cent penetration occurring with the higher dose (not shown).
Comparison of body fluid antimicrobial concentrations with cyst counts obtained from
experiments run in parallel suggest correlations between serum (Figure 4{a)) and lung
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lavage fluid (Figure 4(b)) sulphamethoxazole concentrations and the levels of pulmonary
P. carinii present after 30 administrations of various doses of trimethoprim/
sulphamethoxazole.
Progression of P. carinii infection during trimethoprim/sulphamethoxazole treatment
Groups of scid mice (n = 5) were treated with 100/500 mg/kg/d trimethoprim/
sulphamethoxazole or saline (po, bd, 5 days per week) and killed sequentially to determine
the time course of resolution of P. carinii infection. As shown in Figure 5, although the
cyst count tended to be reduced after one week of treatment (trimethoprim/sul-
phamethoxazole treated, 6-71 + 0-28; saline treated, infected controls,
7-16 + 0-21 log cysts/g lung; P > 0-05, /-test), a statistically significant reduction in cysts
did not occur until the end of two weeks of treatment. This was followed by a dramatic
decline in lung P. carinii load (below the limit of detection) at end of three weeks
of treatment (trimethoprim/sulphamethoxazole treated, 3-97 ± 005; saline treated,
infected controls, 715 ± 0-1 log cysts/g lung; P<00l, f-test). Similarly, reduction
in lung weight in response to trimethoprim/sulphamethoxazole treatment was
delayed until the end of two weeks of treatment (pre-treatment, 0-4 ± 004g; week
one, trimethoprim/sulphamethoxazole 0-40 ± 0-2 g, saline treated, infected controls,
0-42 ± 003 g; week two, trimethoprim/sulphamethoxazole 0-32 ± 0-2 g, saline treated,
infected controls, 0-46 ± 003 g) and continued until the end of the treatment schedule
(trimethoprim/sulphamethoxazole treated, 0-25 ± 0003 g lung; saline treated, infected
controls, 0-41 ± 002 g lung; P < 001, r-test). Circulating WBC levels tended to decline
after one week of trimethoprim/sulphamethoxazole treatment (pre-treatment, leucocytes
7-4 ± 1-861 x 10' L; week one, leucocytes 4-4 ± 1153 x 109 L, saline treated, infected
controls, 6-640 ± 1-541 x 10'L), but only became significantly different from saline
treated, infected controls at the end of two weeks of treatment (trimethoprim/
sulphamethoxazole treated 2-4 ± 0-256 x 10' L, saline treated, infected controls
6 -1
I
I 4 Saline controlsTMP/SMX, 100/500 mg/kg, p.o.
0 1 2 3
Weeks of treatment
Figure 5. Progression of P. carinii infection in scid mice during treatment with trimethoprim/sulphamethox-
azole. P. carinii infected scid mice (n = 5/group) were treated with either 100/500 mg/kg/day
trimethoprim/sulphamethoxazole (# ; bd, po, 5 days per week) or saline (O) and killed after 1, 2 or 3 weeks
(10, 20 or 30 treatments respectively). Symbols represent mean values of log cysts/g lung ± S.E.M.
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Saline controls
Pentamidine 2 mg/kg, 3x/week
Pentamidine 6 mg/kg, 3x/week
Pentamidine 20 mg/kg, 3x/week
TMP/SMX 100/500 mg/kg/day
Log (cyst«/g lung) (mean ± 8.E.M.)
Figure 6. Pentamidine treatment of scid mice infected with P. carinii scid mice (n = 7/group) were treated
with 100/500 trimethoprim/sulphamethoxazole (bd, po, 5 days per week), pentamidine (20, 6, or 2 mg/kg, sc,
three times per week), or saline (po) for 21 days of treatment. One day after the last treatment, mice were killed
and the lung cyst counts were determined.
8-46 ± 1-236 x 109Lblood;P<001;Mest).NofurtherchangesinWBClevelsoccurred
after an additional week of treatment.
Effect of trimethoprim/sulphamethoxazole treatment on scid mice free of P. carinii
In order to determine if changes in body weight, lung weight and circulating blood cells
following trimethoprim/sulphamethoxazole treatment were indeed due to reduction of
pulmonary P. carinii, scid mice of 90 days of age obtained from a colony free of
histologically-detectable P. carinii-were treated either saline (n = 10) or 100/500 mg/kg/d
trimethoprim/sulphamethoxazole (n = 10) as described above. At the end of treatment,
there were no significant differences (P > 005; /-test) between the two groups with respect
to body weights (trimethoprim/sulphamethoxazole, 27-5 + 0-5 g; controls, 26-5 ± 0-5),
lung weights (trimethoprim/sulphamethoxazole 0-157 ± 0004g; controls,
0-159 ± 0004), blood erythrocyte levels (trimethoprim/sulphamethoxazole 9-9 x 1012 L;
controls, 9-3 x 1012 L) or blood leucocyte levels (trimethoprim/sulphamethoxazole,
2-5 ± 0-34 x 10' L; controls, 205 ± 0-14 x 109 L). P. carinii cysts were below the limit
of detectability in all of these mice at the end of treatment.
Effect of pentamidine dose on P. carinii infection in scid mice
Pentamidine is another recommended drug for treatment and prophylaxis of P. carinii
infections, and therefore affords a second standard drug to evaluate the utility of scid mice
as a therapeutic model. Scid mice (n = 7 per group) were treated with
trimethoprim/sulphamethoxazole (100/500 mg/kg/day, po, bd for 5 days per week),
or various doses of pentamidine (20, 6 or 2 mg/kg, sc, three times per week) for 21
days; this corresponds to 60, 18 or 6 mg/kg/week. Macroscopic lesions at the site of
pentamidine injection were not observed. Figure 6 indicates that trimethoprim/
sulphamethoxazole and 60 mg/kg/week pentamidine were both effective in reducing lung
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cyst counts (100/500 mg/kg/d trimethoprim/sulphamethoxazole superior to 60 mg/kg/
week pentamidine, P < 0-01; ANOVA), and the highest dose of pentamidine being
superior to all other doses (P < 001 ; ANOVA). Furthermore, all doses of pentamidine
were effective in reducing lung weight (60 mg/kg/week, 0-24 + 0-06 g; 18 mg/kg/week,
0-32 ± 004 g; 6 mg/kg/week 0-37 ± 001 g; saline treated, infected controls,
1-2 ± 0-02 g), and the highest dose of pentamidine was as effective as 100/500 mg/kg/d
trimethoprim/sulphamethoxazole (0-27 ± 0-06 g; P < 0-01 vs infected controls;
ANOVA). ANOVA analysis also indicated the pentamidine-induced reduction in lung
weight to be dose-dependent in that each dose was significantly different from each other
(P < 0-01). All treatment regimens reduced the circulating WBC levels compared with
infected controls (60 mg/kg/week, 3-216 ± 0-419 x 10' L; 18 mg/kg/week,
4-128 ± 0-658 x 109L; 6 mg/kg/week 4-883 ± 0-499 x lO'L; saline treated, infected
controls, 9-242 ± 1-083 x 109L), however, the dose-dependency of the response with
pentamidine was statistically not significant. No dose of pentamidine was capable of
significantly promoting weight gain nor reducing circulating RBC levels during the course
of treatment (not presented).
Discussion
The development of a variety of in-vitro methodologies to evaluate anti-pneumocystis
compounds (Pifer, Pifer & Woods, 1983; Bartlett, Eichholtz & Smith, 1985; Cushion et al,
1985; Bartlett et al., 1986, 1992; Broughton & Queener, 1991; Comley et al., 1991;
Queener et al., 1991) has not obviated the requirement of in-vivo testing of novel
therapeutic strategies. Previous communications about P. carinii infections in
cortisone-treated mice (Walzer et al., \919b), nude mice (Ueda et al., 1977; Walzer et al.,
1977), CD4+ T-cell-depleted mice (Shellito et al., 1990) and scid mice (Walzer et al,
1979a; Sundberg et al., 1989; Roths et al, 1990; Shultz et al, 1990) have focused on the
progression of pathology (Walzer et al., 1979a; Shultz et al, 1989). Earlier evidence
suggested that these mice are responsive to treatment: although scid mice treated
with trimethoprim/sulphamethoxazole in drinking water (100/500 trimethoprim/
sulphamethoxazole mg/kg/d; Walzer et al, 1979a; Shultz et al., 1989) demonstrated
increased survival times, treatment apparently did not eliminate P. carinii from the lungs
(Shultz et al, 1989); however, no quantitative data have been presented so far. The present
study presents the first rigorous evaluation of the potential of pneumocystis-infected scid
mice as a model for the evaluation of novel agents.
The present study has confirmed several of the features of endogenous infection as
documented by Roths et al (1990): the severity of P. carinii infection, the uniformity of
infection (100% of mice positive for infection), elevated lung weight, and elevated
circulating erythrocytes. Furthermore, recent evidence has indicated that P. carinii
bearing mice can transmit this infection to scid mice free of pneumocystis; recipient mice
apparently uniformly develop a pulmonary infection (Powles et al, 1992). Lastly, scid
mice free of endogenous P. carinii possible could be infected with isolates obtained from
patients (Sethi, 1992), although recent evidence suggests that P. carinii has a restricted
host range (Gigliotti et al., 1993). This evidence indicates that the use of scid mice permits
the establishment of a reliable model of P. carinii pulmonary infections.
Twice per day treatment of scid mice with trimethoprim/sulphamethoxazole resulted in
a linear, dose-dependent reduction of pulmonary P. carinii, but changes in associated
pathology were apparently not linearly dose-dependent; we have found that
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trimethoprim/sulphamethoxazole administered one per day also demonstrates similar
reduction in cyst counts and associated pathology (not presented). Of interest was the
significant increase in body weight, and reduced lung weight and blood WBC levels
obtained with a poorly effective dose of trimethoprim/sulphamethoxazole (10/50 mg/kg/
d). Although this dose was associated with a slight improvement in lung histopathology,
only slight reductions in PAS-staining material and P. carinii cysts were observed. Similar
data were obtained after pentamidine administration, where only the 60 mg/kg/week dose
was capable of reducing the numbers of P. carinii cysts, where as lower doses were able
to reduce lung weights and circulating WBC levels. Although the reason(s) for this remain
unclear, it may be that although low doses of trimethoprim/ sulphamethoxazole or
pentamidine are unable to kill P. carinii, such doses may be sufficient to interfere with
aspects of the metabolism of this organism which are associated with the induction of
pathological changes. However, in comparison to in-vitro data, the serum
(36-7 ± 2-5 mg/L) or lung lavage fluid (0-24 ± 002 mg/L) sulphamethoxazole
concentrations attained one hour after a dose of 10/50 mg/kg/day trimethoprim/sul-
phamethoxazole would be insufficient to inhibit greatly the metabolism or reduce the
viability of this microorganism (Pesanti, 1980; Comley et al., 1991; Martinez & Kovacs,
1993). Nevertheless, this experimental study indicates potentially therapeutic activities of
trimethoprim/sulphamethoxazole doses that result in serum levels 1 h post administration
that are much lower than trough levels achieved clinically during standard high-dose
treatment of P. carinii pneumonia (Blasere/ al., 1993). This might suggest that lower doses
of trimethoprim/sulphamethoxazole may be clinically efficacious and perhaps reduce the
incidence of adverse reactions in AIDS patients treated with this antimicrobial
combination (Lee & Safrin, 1992).
Mice killed after treatment with 100/500 mg/kg/day trimethoprim/ sulphamethoxazole
at various time points demonstrated that neither the reduction in cysts nor resolution of
symptoms of infection were significantly altered before two weeks of treatment (20
doses), indicating that treatment time is a critical facet of this model to evaluate
anti-pneumocystis agents. This delay in the activity of trimethoprim/ sulphamethoxazole
has been reported previously, and a similar effect has been observed for pentamidine
(Schmatz et al., 1992). As in-vitro (Pesanti, 1980; Pifer et al., 1983; Bartlett et al, 1985)
evidence suggests that trimethoprim/sulphamethoxazole is either unable to kill P. carinii,
or has only weak killing activity, the reduction of the cyst counts following administration
to trimethoprim/sulphamethoxazole may require the participation of host defence
systems. Several reports (Masur& Jones, 1978;Pesanti, 1991; Hidalgo etal., 1992; Taylor,
Phillips & Easmon, 1992) have indicated the need for opsonins (antibody or, to a lesser
extent, complement; Hidalgo et al., 1992), or activation of macrophages by interferon y
(Pesanti, 1991), for efficient phagocytosis of P. carinii by macrophages or neutrophils.
Although complement is likely to be unaffected, scid mice are unable to mount an
antibody response to provide efficient opsonisation, and this apparently prevents the
control of P. carinii infections (Roths et al., 1990). In light of these restraints of the host
defence system, it may be that trimethoprim/sulphamethoxazole is indeed 'cidal in vivo
or is able to alter the microorganism so that it is more readily phagocytosed, similar to
the effect of antibiotics on bacteria (van den Broek, 1989).
Limited pharmacokinetic analysis suggested a correlation between the level of
sulphamethoxazole in serum and lung lavage fluid one hour post administration of
various doses of trimethoprim/sulphamethoxazole and reduction of lung P. carinii
occurring after 30 administrations of those doses. Recent evidence (Walzer et al., 1992a)
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suggests that the anti-pneumocystis activity of this antimicrobial combination is largely
due to sulphamethoxazole. Although body fluid levels of sulphamethoxazole (and
A -^acetyl sulphamethoxazole) were not linear with dose, the body fluid levels attained were
significantly different between doses. Trimethoprim was not detected in serum or lung
lavage fluid at one hour post administration of any dose of trimethoprim/
sulphamethoxazole. It is likely that this represents rapid elimination of this compound
in mice as we have determined (unpublished) that in Balb/c mice, the genetic background
of the scid mice used in the present study, trimethoprim has a Tl/2 of approximately 2 h
in serum or lung lavage fluid following im or po administration of 100/500 mg/kg/day
trimethoprim/sulphamethoxazole, whereas sulphamethoxazole has a Tip of about 20 h
in serum and about 10 h in lung lavage fluid. Although the Tin of sulphamethoxazole in
Balb/c mice is similar to that in humans (8-6 h (Grose, Bodey & Loo, 1979); 11 h (Kaplan
et al., 1973); 14 h (Stevens et al., 1991)), the Tl/2 of trimethoprim in mice is considerably
shorter than the Tip. of trimethoprim in humans (7-6 h (Grose et al., 1979); 11 h (Kaplan
et al., 1973); 13-6 h (Stevens et al., 1991)). This confirms previous observations of rapid
elimination of trimethoprim in rodents (Walzer et al., 1992a). A previous study (Walzer
et al., 1992a), demonstrated apparent accumulation of trimethoprim without concurrent
accumulation of sulphamethoxazole in dexamethasone-immunosuppressed rats.
However, in the present study, no evidence of trimethoprim accumulation was apparent
in scid mice, although our studies demonstrate dose-dependent increases in serum
sulphamethoxazole levels 1 h post administration in scid mice.
Taken together, the data obtained in the present study using compounds with proven
anti-pneumocystis activity has demonstrated that scid mice bearing endogenous P. carinii
infection are amenable to chemotherapeutic intervention. Both trimethoprim/
sulphamethoxazole and pentamidine demonstrated dose-dependent reduction in
pulmonary P. cariniicysts, and in the case of trimethoprim/sulphamethoxazole, this effect
was correlated to the concentration of sulphamethoxazole in both serum and lung lavage
fluid, but required at least two weeks of treatment before a significant reduction of P.
carinii could be observed. However, resolution of a variety of indices of infection were
not correlated, in a linear fashion, to antimicrobial dose or the reduction of cysts. This
model of P. carinii pulmonary infection is likely to be useful for the evaluation of novel
anti-pneumocystis compounds and, because of the treatment-dependent resolution of
associated pathology, may also be useful for exploring novel treatment modalities.
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